<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04647201</url>
  </required_header>
  <id_info>
    <org_study_id>SGI-2020-11</org_study_id>
    <nct_id>NCT04647201</nct_id>
  </id_info>
  <brief_title>Study of Biomarkers in Patients of Sepsis Complicated With Gastrointestinal Dysfunction</brief_title>
  <official_title>Study of Biomarkers in Blood and Tissue Samples of Septic Patients Complicated With Gastrointestinal Dysfunction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jianbo Yu</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tianjin Nankai Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      1. Title: Study of Biomarkers in Patients of Sepsis Complicated With Gastrointestinal&#xD;
           Dysfunction&#xD;
&#xD;
        2. Research center: Single-center study.&#xD;
&#xD;
        3. Design of the research: A prospective and cohort study.&#xD;
&#xD;
        4. Object of the research: Patients with age≥18 years those who meet the diagnostic&#xD;
           criteria of sepsis 3.0 complicated with GI and grouped into GI group and non-GI adults&#xD;
           as control.&#xD;
&#xD;
        5. Sample size of the research: Not less than 30 patients in each group.&#xD;
&#xD;
        6. Research approach: After admission to ICU, patients were assigned to the indicated&#xD;
           groups according to the criteria. In addition, blood samples were collected within 24&#xD;
           hours for detecting serum levels of HO-1, PINK1, PLK1as well as oxidative stress and&#xD;
           inflammatory markers.For those who requiring intestinal surgery as treatment, the&#xD;
           intestinal tissue specimens are retained.&#xD;
&#xD;
        7. Aim of the research: The find out the potential biomarkers in serum to help the diagnose&#xD;
           and management of gastrointestinal dysfunction in septic patients.&#xD;
&#xD;
        8. Statistical analysis: Analytical study.&#xD;
&#xD;
        9. The estimated duration of the study#1-2 years.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a single-center, prospective, cohort study. In this study, the serum samples of&#xD;
      septic patients complicated with or without GI are detected. The serum levels of HO-1, PINK1,&#xD;
      PLK1as well as oxidative stress and inflammatory markers are compared in different groups.&#xD;
      For those who requiring intestinal surgery as treatment, the intestinal tissue specimens are&#xD;
      retained. Meanwhile, the clinical symptoms, intestinal motility indicators and intestinal&#xD;
      barrier indicators are recorded. In addition, a biomarker model was established to provide&#xD;
      important reference for diagnose and management of gastrointestinal dysfunction in septic&#xD;
      patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 23, 2020</start_date>
  <completion_date type="Anticipated">June 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Multivariate data analysis of the metabolites</measure>
    <time_frame>an average of one year</time_frame>
    <description>Record the different metabolites between the control group and septic patients</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Multivariate data analysis of the metabolites</measure>
    <time_frame>an average of one year</time_frame>
    <description>Record the different metabolites between the septic patient with or without GI</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Screening of differentially expressed metabolites as potential mortality predictors for sepsis complicated with GI</measure>
    <time_frame>an average of one year</time_frame>
    <description>Investigated the metabolites to distinguish the non-survivors from the survivors of sepsis complicated with GI</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Sepsis</condition>
  <condition>Gastrointestinal Dysfunction</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <description>Non-sepsis and non-GI adults</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sepsis patients without GI</arm_group_label>
    <description>Patients who meet the criteria of sepsis3.0 with AGI grade I or less</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sepsis patients with GI</arm_group_label>
    <description>Patients who meet the criteria of sepsis3.0 with AGI grade II or above</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Adult patients with sepsis complicated with GI&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. At least 18 years old&#xD;
&#xD;
          2. Patients with sepsis who meet the criteria for sepsis 3.0&#xD;
&#xD;
          3. Patients complicated gastrointestinal dysfunction with AGI grade II or above&#xD;
&#xD;
          4. Agree to participate in this study and sign informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Refuse to participate in this study&#xD;
&#xD;
          2. Those who have chronic gastrointestinal diseases such as Crohn's disease and&#xD;
             ulcerative colitis&#xD;
&#xD;
          3. Those who have recently used gastrointestinal motility drugs and within 5 times the&#xD;
             half-life&#xD;
&#xD;
          4. Those who are participating in other drug clinical trials&#xD;
&#xD;
          5. Patient with HIV infection, patients in pregnancy or breast stage&#xD;
&#xD;
          6. In the opinion of the attending physician or researcher, there are other conditions&#xD;
             that are not appropriate for the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jianbo Yu, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Tianjin Nankai Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yingya Cao, MD</last_name>
    <phone>15055324662</phone>
    <email>caoyingya1990@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jianbo Yu, PhD</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Tianjin Nankai Hospital</name>
      <address>
        <city>Tianjin</city>
        <zip>300100</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Yingya Cao, MD</last_name>
      <phone>15055324662</phone>
      <email>caoyingya1990@126.com</email>
    </contact>
    <contact_backup>
      <last_name>Jianbo Yu, PhD</last_name>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Assimakopoulos SF, Triantos C, Thomopoulos K, Fligou F, Maroulis I, Marangos M, Gogos CA. Gut-origin sepsis in the critically ill patient: pathophysiology and treatment. Infection. 2018 Dec;46(6):751-760. doi: 10.1007/s15010-018-1178-5. Epub 2018 Jul 12.</citation>
    <PMID>30003491</PMID>
  </reference>
  <reference>
    <citation>Reintam Blaser A, Poeze M, Malbrain ML, Björck M, Oudemans-van Straaten HM, Starkopf J; Gastro-Intestinal Failure Trial Group. Gastrointestinal symptoms during the first week of intensive care are associated with poor outcome: a prospective multicentre study. Intensive Care Med. 2013 May;39(5):899-909. doi: 10.1007/s00134-013-2831-1. Epub 2013 Jan 31.</citation>
    <PMID>23370829</PMID>
  </reference>
  <reference>
    <citation>Blaser A, Padar M, Tang J, Dutton J, Forbes A. Citrulline and intestinal fatty acid-binding protein as biomarkers for gastrointestinal dysfunction in the critically ill. Anaesthesiol Intensive Ther. 2019;51(3):230-239. doi: 10.5114/ait.2019.86049. Review.</citation>
    <PMID>31418255</PMID>
  </reference>
  <reference>
    <citation>Reintam Blaser A, Regli A, De Keulenaer B, Kimball EJ, Starkopf L, Davis WA, Greiffenstein P, Starkopf J; Incidence, Risk Factors, and Outcomes of Intra-Abdominal (IROI) Study Investigators. Incidence, Risk Factors, and Outcomes of Intra-Abdominal Hypertension in Critically Ill Patients-A Prospective Multicenter Study (IROI Study). Crit Care Med. 2019 Apr;47(4):535-542. doi: 10.1097/CCM.0000000000003623.</citation>
    <PMID>30608280</PMID>
  </reference>
  <reference>
    <citation>Greis C, Rasuly Z, Janosi RA, Kordelas L, Beelen DW, Liebregts T. Intestinal T lymphocyte homing is associated with gastric emptying and epithelial barrier function in critically ill: a prospective observational study. Crit Care. 2017 Mar 22;21(1):70. doi: 10.1186/s13054-017-1654-9.</citation>
    <PMID>28327177</PMID>
  </reference>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 22, 2020</study_first_submitted>
  <study_first_submitted_qc>November 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 30, 2020</study_first_posted>
  <last_update_submitted>November 22, 2020</last_update_submitted>
  <last_update_submitted_qc>November 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Tianjin Nankai Hospital</investigator_affiliation>
    <investigator_full_name>Jianbo Yu</investigator_full_name>
    <investigator_title>Department of Anesthesiology, Director, Chief physician, Professor, Doctoral tutor</investigator_title>
  </responsible_party>
  <keyword>sepsis</keyword>
  <keyword>gastrointestinal dysfunction</keyword>
  <keyword>biomarkers</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sepsis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>All of the individual participant data collected during the trial,after de-identification will be shared.And anyone who wishes to acess the date will beavailable for any purpose</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

